Liquidia Corp
NASDAQ:LQDA

Watchlist Manager
Liquidia Corp Logo
Liquidia Corp
NASDAQ:LQDA
Watchlist
Price: 33.38 USD 2.42% Market Closed
Market Cap: 2.9B USD

Operating Margin
Liquidia Corp

-155%
Current
-480%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-155%
=
Operating Profit
-107.3m
/
Revenue
69.2m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Liquidia Corp
NASDAQ:LQDA
2.9B USD
-155%
US
Eli Lilly and Co
NYSE:LLY
971.9B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
509.1B USD
27%
CH
Roche Holding AG
SIX:ROG
252.3B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
208.5B GBP
24%
CH
Novartis AG
SIX:NOVN
202.4B CHF
33%
US
Merck & Co Inc
NYSE:MRK
249.5B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
147B USD
29%
No Stocks Found

Liquidia Corp
Glance View

Market Cap
2.9B USD
Industry
Pharmaceuticals

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina and currently employs 47 full-time employees. The company went IPO on 2018-07-26. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The firm is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.

LQDA Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-155%
=
Operating Profit
-107.3m
/
Revenue
69.2m
What is the Operating Margin of Liquidia Corp?

Based on Liquidia Corp's most recent financial statements, the company has Operating Margin of -155%.

Back to Top